Hansa hands SERB regional Idefirix rights in €115M deal

Hansa Biopharma has struck a €115 million licensing deal that gives SERB Pharmaceuticals exclusive development and commercialization rights to Idefirix (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and the Middle East and North Africa. Under the agreement announced May 19, 2026, Hansa will receive €110 million upfront and another €5 million tied to full European Commission approval, while retaining rights in the U.S., Japan, and other markets. Idefirix is already authorized in Europe for desensitization treatment in highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. (globenewswire.com)

Why it matters: For veterinary professionals, this is mainly a window into how specialty biologics companies are reshaping commercialization strategy around rare, high-complexity therapies. Hansa appears to be trading direct regional control for near-term capital, commercial scale, and a partner with established rare-disease infrastructure in more than 100 countries. That kind of dealmaking can affect how quickly advanced immunology and transplant-adjacent platforms move through regulatory and market access pathways, even if this product is in human medicine. Hansa has also been under pressure to improve Idefirix performance in Europe: its 2025 annual report said European access was growing, but first-quarter 2026 product sales fell year over year. (globenewswire.com)

What to watch: Watch whether SERB can expand uptake in Europe and MENA, and whether Hansa’s U.S. regulatory path stays on track ahead of the FDA’s December 19, 2026 PDUFA date for imlifidase. (globenewswire.com)